Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …
ME Wechsler, A Menzies-Gow… - The Lancet …, 2022 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral …
ME Wechsler, G Colice, JM Griffiths, G Almqvist… - Respiratory …, 2020 - Springer
Background Many patients with severe asthma continue to experience asthma symptoms
and exacerbations despite standard-of-care treatment. A substantial proportion of these …
and exacerbations despite standard-of-care treatment. A substantial proportion of these …
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of …
A Menzies-Gow, S Ponnarambil, J Downie… - Respiratory …, 2020 - Springer
Background Tezepelumab is a human monoclonal antibody that blocks the activity of the
epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid …
epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid …
[HTML][HTML] Tezepelumab in adults with uncontrolled asthma
J Corren, JR Parnes, L Wang, M Mo… - … England Journal of …, 2017 - Mass Medical Soc
Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
A Menzies-Gow, ME Wechsler… - The Lancet …, 2023 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR …
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR …
[HTML][HTML] Tezepelumab in adults and adolescents with severe, uncontrolled asthma
A Menzies-Gow, J Corren, A Bourdin… - … England Journal of …, 2021 - Mass Medical Soc
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma …
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma …
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a …
S Diver, L Khalfaoui, C Emson, SE Wenzel… - The Lancet …, 2021 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies …
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies …
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and …
A Menzies-Gow, G Colice, JM Griffiths, G Almqvist… - Respiratory …, 2020 - Springer
Background Patients with severe, uncontrolled asthma have a significant unmet need for
new treatments that have broader effects on airway inflammation, and that provide greater …
new treatments that have broader effects on airway inflammation, and that provide greater …
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
J Corren, TH Pham, E Garcia Gil, K Sałapa, P Ren… - Allergy, 2022 - Wiley Online Library
Background Tezepelumab is a human monoclonal antibody that blocks activity of thymic
stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130) …
stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130) …
Tezepelumab: first approval
SM Hoy - Drugs, 2022 - Springer
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the
pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class …
pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class …